Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre–Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward
Year: 2021
Type: review
Abstract: Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and cumulative gene–environment interactions over a lifetime. The evolving understanding of COPD biology provides novel opportunities for prevention, early diagnosis, and intervention. To advance these concepts, we propose therapeutic trials in two major groups of subjects: “young” individuals with COPD and those with pre-COPD. Given that lungs grow to about 20 years of age and begin to age at approximately 50 years, we consider “young” patients with COPD those patients in the age range of 20–50 years. Pre-COPD relates to individuals of any age who have respiratory symptoms with or without structural and/or functional abnormalities, in the absence of airflow limitation, and who may develop persistent airflow limitation over time. We exclude from the current discussion infants and adolescents because of their unique physiological context and COPD in older adults given their representation in prior randomized controlled trials (RCTs). We highlight the need of RCTs focused on COPD in young patients or pre-COPD to reduce disease progression, providing innovative approaches to identifying and engaging potential study subjects. We detail approaches to RCT design, including potential outcomes such as lung function, patient-reported outcomes, exacerbations, lung imaging, mortality, and composite endpoints. We critically review study design components such as statistical powering and analysis, duration of study treatment, and formats to trial structure, including platform, basket, and umbrella trials. We provide a call to action for treatment RCTs in 1) young adults with COPD and 2) those with pre-COPD at any age.
Authors: Fernando J. Martinez, Alvar Agusti, Bartolome R. Celli, MeiLan K. Han, James P. Allinson, Surya P. Bhatt, Peter Calverley, Sanjay H. Chotirmall, Badrul Chowdhury, Patrick Darken, Carla A. Da Silva, Gavin Donaldson, Paul Dorinsky, Mark Dransfield, Rosa Faner, David M. Halpin, Paul Jones, Jerry A. Krishnan, Nicholas Locantore, Fernando D. Martinez, Hana Mullerova, David Price, Klaus F. Rabe, Colin Reisner, Dave Singh, Jørgen Vestbo, Claus F. Vogelmeier, Robert A. Wise, Ruth Tal-Singer, Jadwiga A. Wedzicha
Institutions: NewYork–Presbyterian Hospital, Weill Cornell Medicine, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer, Brigham and Women's Hospital, Harvard University, Michigan Medicine, Imperial College London, University of Alabama at Birmingham, University of Liverpool, Nanyang Technological University, Savara Pharmaceuticals (United States), AstraZeneca (United States), AstraZeneca (Sweden), Universitat de Barcelona, Royal Devon and Exeter Hospital, St George's, University of London, University of Illinois Chicago, University of Arizona, AstraZeneca (United Kingdom), University of Aberdeen, Observational & Pragmatic Research Institute, Christian-Albrechts-Universität zu Kiel, German Center for Lung Research, LungenClinic Grosshansdorf, Medicines Evaluation Unit, Manchester University NHS Foundation Trust, Philipps University of Marburg, Johns Hopkins University, Johns Hopkins Medicine, COPD Foundation
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: chronic obstructive pulmonary disease, pre-COPD, young adults, early intervention, disease progression, randomized controlled trials, trial design, platform trials, basket trials, umbrella trials, lung function, patient-reported outcomes, COPD exacerbations, lung imaging, statistical power, gene-environment interaction
Open Access status: green
OpenAlex ID: W3206293932
